mds: an update on pevonedistat plus azacitidine
Published 4 years ago • 233 plays • Length 0:44Download video MP4
Download video MP3
Similar videos
-
1:31
pevaz update: pevonedistat & azacitidine in r/r mds and mds/mpn after dnmti failure
-
1:15
the diagnosis and management of mds/mpn with neutrophilia (atypical cml)
-
1:45
updates on the treatment of mds
-
2:20
pevonedistat, azacitidine and venetoclax triplet therapy for aml, mds and cmml
-
1:47
pevonedistat with azacitidine for high-risk mds
-
2:11
update on phase i/ii study of azacitidine, venetoclax and gilteritinib in patients with flt3 aml
-
1:33
the current guidelines and therapies for tp53-mutated mds and aml
-
1:32:42
mds & covid-19 vaccine
-
4:32
myelodysplastic syndromes: overview, diagnosis, therapy, and more
-
1:45
deciding which patients with mpns are suitable candidates for interferon-based therapy
-
3:05
high-risk mds: pevonedistat and azacitidine vs azacitidine alone
-
2:43
novel therapies in the future of mds treatment
-
2:18
ven-aza versus intensive chemotherapy as bridging therapy in patients with mds
-
1:21
hmas for mds- a party of one
-
4:44
establishing the clinical benchmark of azacitidine in patients with mds
-
0:55
the role of rna modifications in mds and aml
-
1:17
phase ii study of tosedostat in mds
-
1:09
dec-c plus venetoclax in hr-mds and cmml: an analysis using different response criteria
-
1:41
an overview of the mds diagnosis pathway
-
1:54
fusion-aml-001: molecular changes associated with azacitidine & durvalumab in tp53m aml and hr-mds
-
1:59
phase i study of pevonedistat, azacitidine, and venetoclax in patients with r/r aml